Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965798 | 0.86 | CA12 (0.37) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7203924 | 0.83 | AAK1 (0.39) | SLC7A5GRM6ITGA4ITGB7AAK1 | |
| SCHEMBL2159034 | 0.78 | MAPT (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29168896 | 0.74 | GABRA1 (0.41) | SLC7A5ITGA4ITGB7AAK1LTA4H | |
| SCHEMBL27887663 | 0.74 | ALDH1A1 (0.41) | KMT2A | |
| SCHEMBL498660 | 0.73 | MYC (0.42) | AAK1LMNA | |
| SCHEMBL6192174 | 0.73 | GAA (0.42) | SLC7A5AAK1LMNAKMT2A | |
| SCHEMBL10489985 | 0.73 | FABP3 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5323694 | 0.73 | AAK1 (0.35) | SLC7A5GRM6ITGA4ITGB7AAK1 | |
| SCHEMBL3414451 | 0.72 | LMNA (0.43) | GRM6ITGA4ITGB7AAK1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220098128-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11040925-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190330124-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10202316-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-12-28 | — | — | US | disclosed |
| EP-3239144-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | Celgene Corporation (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9732064-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170158579-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
| WO-2014110558-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES | DEUTERX, LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | CA12 2749/4885CA1 2563/4885CA2 2467/4885 |
| US-11040925-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, TLR5, IDO1 | CA12 2968/4885CA1 2462/4885CA2 2335/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | CA12 2686/4885CA1 1296/4885CA2 1163/4885 |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CA12 2968/4885CA1 2462/4885CA2 2335/4885 |
| US-20190330124-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CA12 2968/4885CA1 2462/4885CA2 2335/4885 |
| US-20220098128-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL15, CXCR5 | CA12 2749/4885CA1 2563/4885CA2 2467/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | CA12 2138/4885CA1 1453/4885CA2 748/4885 |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | CA12 2138/4885CA1 1453/4885CA2 748/4885 |
| US-20170158579-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CA12 2968/4885CA1 2462/4885CA2 2335/4885 |
| US-10202316-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, TLR5, IDO1 | CA12 2968/4885CA1 2462/4885CA2 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.